Tag Archives: clients

Traverse Biosciences to collaborate with SUNY Upstate Medical University

Posted on by
Reply

Traverse Biosciences has announced a collaboration with SUNY Updated Medical University on a $164,689 Peer Reviewed Medical Research Program (PRMRP) Discovery Award from the U.S. Department of Defense. The research will be led by Gary Nieman, Associate Professor and Senior Research Scientist in the Department of Surgery and will evaluate the effectiveness of the company’s lead drug candidate, TRB-N0224, to treat acute lung injury, including acute respiratory distress syndrome (ARDS). Read more here.

TraverseBioLogo2

Intensity Therapeutics, Inc. Raises $10 Million Series A

Posted on by
Reply

Intensity

 

 

Intensity Therapeutics has announced that it has secured $10 million in new capital from a Series A preferred stock financing. Participants included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors and family offices.

Lead by President and CEO Lewis H. Bender, the company is developing a proprietary cancer immunotherapy products. In a statement Bender said, “Our lead drug, INT230-6, has shown strong results in severe murine models of metastatic cancer via a combination of direct tumor killing and immune system activation.” According to Bender, “Proceeds will be used to fund operations, manufacture the clinical supplies, permit the needed regulatory filings and conduct a series of clinical trial cohorts in cancer patients with various tumor types.”

The company has also announced the addition of Dr. Decalan Doogan former Senior Vice President and Head of worldwide drug development at Pfizer and Emer Leahy, Ph.D., CEO of PsychoGenics will join Intensity’s Board of Directors. More information about Intensity Therapeutics can be found on the company’s website: www.intensitytherapeutics.com.

Rgenix Announces $33M Series B Financing

Posted on by
Reply

regenix_web1Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP. The financing will support clinical development of Rgenix’s lead drug candidates, RGX-104 and RGX-202, as well as further development of its therapeutics pipeline.

In connection with the financing, Nilesh Kumar of Novo Ventures and Antoine Papiernik of Sofinnova Partners will join the Rgenix Board of Directors together with existing members, including Executive Chairman Eric Rowinsky, M.D., Masoud Tavazoie, M.D. Ph.D., Nancy Chang, Ph.D., and Saeed Tavazoie, Ph.D. Read the full press release about Rgenix’s financing here.

Celmatix CEO Named to Fortune’s Entrepreneurs List

Posted on by
Reply

Piraye Yurttas Beim, co-founder and CEO of Celmatix was named to “The Fortune Entrepreneurs List”. Celmatix’s technology enabled products analyze big data and genomics to optimize the treatment of infertility and allow for proactive fertility management. Read the feature on Dr. Beim on Fortune.com.